

# **APPENDIX 1**

## **Submissions and additional information received by the committee**

### **Submissions**

- 1 Private Mental Health Consumer Carer Network (Australia)
- 2 Geraldine Robertson
- 3 Brian Stafford
- 4 Chronic Illness Alliance
- 5 Diabetes Australia
- 6 National Association of People Living with HIV/AIDS
- 7 Council of Social Service Network
- 8 Cancer Voices Australia
- 9 Consumers Health Forum of Australia
- 10 SANE Australia
- 11 iNova Pharmaceuticals (Aust) Pty Ltd
- 12 Research Australia
- 13 Mental Illness Fellowship of Australia
- 14 Australian Pain Management Association Inc.
- 15 Painaustralia Limited
- 16 Australian Medical Association
- 17 Brain Tumour Alliance Australia Incorporated
- 18 Cystic Fibrosis Australia
- 19 Deakin Health Economics, Deakin University
- 20 The Australian Lung Foundation
- 21 Hepatitis Australia
- 22 Osteoporosis Australia
- 23 Novo Nordisk
- 24 Breast Cancer Network Australia
- 25 Arthritis Australia
- 26 Positive Life NSW
- 27 Australasian College of Dermatologists
- 28 ACON
- 29 Sanofi
- 30 Queensland Positive People

- 31 Generic Medicines Industry Association
- 32 Joint submission from Cancer Council Australia, the Clinical Oncological Society of Australia and the Medical Oncology Group of Australia
- 33 Health Consumers' Council (WA)
- 34 Medical Oncology Group of Australia
- 35 Pfizer Australia
- 36 Medicines Australia
- 37 Janssen-Cilag Pty Ltd
- 38 Mundipharma Pty Ltd
- 39 Roche
- 40 Arafmi Mental Health Carers and Friends Association (WA) Inc
- 41 Australian Federation of AIDS Organisations
- 42 Amgen Australia Pty Ltd
- 43 MS Australia
- 44 GlaxoSmithKline Australia
- 45 Allergan Australia Pty Ltd
- 46 The Department of Health and Ageing
- 47 AstraZeneca Australia Pty Ltd
- 48 Elizabeth Trapani
- 49 Cancer Voices NSW
- 50 National Seniors Australia
- 51 Janne Graham
- 52 Carol Hughes
- 53 Mental Health Council of Australia
- 54 Elizabeth Graham
- 55 Name withheld
- 56 Australian Pompe's Association
- 57 Matthew Peters
- 58 Valerie Hanrahan
- 59 Health Consumers NSW
- 60 Fabry Support Group Australia
- 61 The Royal Australasian College of Physicians
- 62 Northern Territory Government Department of Health
- 63 Department of Health Western Australia
- 64 Confidential
- 65 Dr Kathryn Antioch

---

**Additional information received**

- 1 Generic Medicines Industry Association (GMiA), *Case study – amiloride*, tabled at the Melbourne public hearing on 21 July 2011
- 2 Chronic Illness Alliance, 'Prescription drug subsidies in Australia and New Zealand', *Australian Prescriber*, Vol 33, No. 1, February 2010, tabled at the Melbourne public hearing on 21 July 2011
- 3 Allergan Australia, Answers to Questions on Notice taken at the Melbourne public hearing on 21 July 2011, provided on 29 July 2011
- 4 Mundipharma Australia, Answers to Questions on Notice taken at the Melbourne public hearing on 21 July 2011 and additional information, provided on 5 August 2011
- 5 Janssen-Cilag Australia, Answers to Questions on Notice taken at the Melbourne public hearing on 21 July 2011 and additional information, provided on 5 August 2011
- 6 Medicines Australia, Answers to Questions on Notice taken at the Canberra public hearing on 25 July 2011, provided on 8 August 2011
- 7 Pharmaceutical Benefits Advisory Committee, Answers to Questions on Notice taken at the Canberra public hearing on 25 July 2011, provided on 9 August 2011
- 8 Pfizer Australia, Answers to Questions on Notice taken at the Melbourne public hearing on 21 July 2011 and additional information, provided on 10 August 2011
- 9 Department of Health and Ageing, Answers to Questions on Notice taken at the Canberra public hearing on 25 July 2011, provided on 12 August 2011

